Grandfield & Dodd LLC continued to hold its stake in shares of C.R. Bard Inc. (NYSE:BCR) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,311 shares of the company’s stock at the end of the second quarter. Grandfield & Dodd LLC’s holdings in C.R. Bard were worth $308,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. BlackRock Institutional Trust Company N.A. increased its stake in shares of C.R. Bard by 4.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 2,234,725 shares of the company’s stock worth $452,912,000 after buying an additional 98,144 shares during the period. BlackRock Fund Advisors increased its stake in shares of C.R. Bard by 8.5% in the first quarter. BlackRock Fund Advisors now owns 1,886,656 shares of the company’s stock worth $382,369,000 after buying an additional 147,571 shares during the period. Renaissance Technologies LLC increased its stake in shares of C.R. Bard by 23.4% in the first quarter. Renaissance Technologies LLC now owns 1,355,300 shares of the company’s stock worth $274,679,000 after buying an additional 256,800 shares during the period. Standard Life Investments LTD acquired a new stake in shares of C.R. Bard during the second quarter worth about $241,642,000. Finally, BlackRock Group LTD increased its stake in shares of C.R. Bard by 15.0% in the first quarter. BlackRock Group LTD now owns 893,218 shares of the company’s stock worth $181,028,000 after buying an additional 116,835 shares during the period. Institutional investors own 87.90% of the company’s stock.
C.R. Bard Inc. (NYSE:BCR) traded up 0.40% during midday trading on Thursday, reaching $222.25. The company’s stock had a trading volume of 390,118 shares. C.R. Bard Inc. has a one year low of $172.21 and a one year high of $239.43. The firm has a 50 day moving average price of $221.59 and a 200 day moving average price of $219.93. The firm has a market cap of $16.33 billion, a P/E ratio of 51.69 and a beta of 0.50.
C.R. Bard (NYSE:BCR) last issued its earnings results on Tuesday, July 26th. The company reported $2.54 EPS for the quarter, topping the Zacks’ consensus estimate of $2.47 by $0.07. The business had revenue of $931.50 million for the quarter, compared to the consensus estimate of $915.22 million. C.R. Bard had a net margin of 9.20% and a return on equity of 48.43%. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.27 EPS. Equities research analysts forecast that C.R. Bard Inc. will post $10.17 EPS for the current fiscal year.
BCR has been the topic of a number of recent analyst reports. Wells Fargo & Co. upgraded C.R. Bard from a “market perform” rating to an “outperform” rating in a research report on Friday, September 16th. Leerink Swann reiterated a “market perform” rating and issued a $233.00 price objective (down previously from $240.00) on shares of C.R. Bard in a research report on Thursday, July 28th. Barclays PLC increased their price objective on C.R. Bard from $224.00 to $235.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 27th. Zacks Investment Research downgraded C.R. Bard from a “buy” rating to a “hold” rating in a research report on Thursday, August 4th. Finally, Morgan Stanley reiterated a “hold” rating and issued a $240.00 price objective on shares of C.R. Bard in a research report on Thursday, July 28th. Thirteen investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $233.00.
In other news, Chairman Timothy M. Ring sold 110,000 shares of the stock in a transaction that occurred on Monday, September 26th. The shares were sold at an average price of $228.96, for a total transaction of $25,185,600.00. Following the transaction, the chairman now directly owns 96,030 shares in the company, valued at $21,987,028.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP John A. Deford sold 7,928 shares of the stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $221.06, for a total transaction of $1,752,563.68. The disclosure for this sale can be found here. 0.97% of the stock is currently owned by company insiders.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.